| Code | CSB-RA868278MB8HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Tildrakizumab-ASMN, targeting the p19 subunit of interleukin-23 (IL23A). IL-23 is a heterodimeric cytokine that plays a critical role in inflammatory and immune responses by promoting the differentiation and survival of Th17 cells, which produce pro-inflammatory cytokines including IL-17. The IL-23/Th17 axis is implicated in the pathogenesis of various autoimmune and inflammatory conditions, particularly chronic plaque psoriasis, psoriatic arthritis, and inflammatory bowel disease. Dysregulated IL-23 signaling contributes to sustained inflammation and tissue damage in these disorders.
Tildrakizumab-ASMN is an FDA-approved humanized IgG1κ monoclonal antibody that specifically binds to the p19 subunit of IL-23, preventing its interaction with the IL-23 receptor and subsequent downstream signaling. This biosimilar antibody serves as a valuable research tool for investigating IL-23-mediated inflammatory pathways, studying mechanisms of autoimmune disease progression, evaluating therapeutic targets in dermatological and rheumatological conditions, and supporting preclinical studies in immunology and inflammation research.
There are currently no reviews for this product.